Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness (i.e. tolerance). This has been shown for the short acting beta agonist salbutamol and the long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours. The onset of tolerance to salbutamol is not known.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| salbutamol | Active Comparator |
| |
| placebo | Placebo Comparator | 200mcg twice daily for a total of 7 doses |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| salbutamol | Drug | 200mcg twice daily for a total of 7 doses |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Airway responsiveness as a measure of salbutamol bronchoprotection | Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance. | ten minutes post 200mcg salbutamol on day 1 |
| Airway responsiveness as a measure of salbutamol bronchoprotection | Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance. | ten minutes post 200mcg salbutamol on day 3 |
| Airway responsiveness as a measure of bronchoprotection. The primary outcome is to determine the onset of this tolerance. | Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance. | ten minutes post 200mcg salbutamol on day 5 |
| Airway responsiveness as a measure of salbutamol bronchoprotection | Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance. | ten minutes post 200mcg salbutamol on day 7 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Donald W Cockcroft, MD | University of Saskatchewan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Saskatchewan | Saskatoon | Saskatchewan | S7N 0W8 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23176887 | Derived | Stewart SL, Martin AL, Davis BE, Cockcroft DW. Salbutamol tolerance to bronchoprotection: course of onset. Ann Allergy Asthma Immunol. 2012 Dec;109(6):454-7. doi: 10.1016/j.anai.2012.08.003. Epub 2012 Aug 22. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000420 | Albuterol |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
200mcg twice a day for a total of 7 doses (3.5 days). |
|
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D000588 |
| Amines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |